News
New Study | Increasing use of Precivia® in the UK
FCI is pleased to share with you this new clinical data study published in the European Journal Of Ophthalmology about the increasing use of Precivia® in the UK.
Background
Intravitreal anti-VEGF injections are the most frequently performed outpatient procedure in the UK, the need for which continues to rise. To meet this demand, injection assist devices such as Precivia® are increasingly adopted to aid in their prompt and safe delivery. This study presents data on the usage of Precivia® intravitreal injection assist device across two district general hospitals and its distribution across the UK over five years.
Methods
A retrospective review was undertaken of all Precivia® assisted intravitreal injections delivered at Great Western Hospitals NHS Trust (GWH), and Gloucestershire and Cheltenham Hospitals NHS Trust (GCH) between 2015–2020. Data were also obtained from the Precivia® device UK distributor; Veni Vidi Medical.
A retrospective review was undertaken of all Precivia® assisted intravitreal injections delivered at Great Western Hospitals NHS Trust (GWH), and Gloucestershire and Cheltenham Hospitals NHS Trust (GCH) between 2015–2020. Data were also obtained from the Precivia® device UK distributor; Veni Vidi Medical.
Ahmed I, Maghsoudlou P, Shah N. Increasing trends in the use of the Precivia® intravitreal injection assist device across the UK. European Journal of Ophthalmology. 2024.
For more information about this device, make sure to visit the Precivia® product page.